These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 7671099

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Management of Paget's disease of bone.
    Langston AL, Ralston SH.
    Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
    Paterson AH, Kanis JA, Powles TJ, McCloskey E, Hanson J, Ashley S.
    Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
    [Abstract] [Full Text] [Related]

  • 12. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A.
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [Abstract] [Full Text] [Related]

  • 13. Bisphosphonates: from bench to bedside.
    Russell RG.
    Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
    [Abstract] [Full Text] [Related]

  • 14. The pharmacology and therapeutic utility of bisphosphonates.
    Lourwood DL.
    Pharmacotherapy; 1998 Apr; 18(4):779-89. PubMed ID: 9692651
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonates: preclinical aspects and use in osteoporosis.
    Fleisch HA.
    Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
    [Abstract] [Full Text] [Related]

  • 16. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D, Mossetti G, Viceconti R, Sorrentino M, Nunziata V.
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [Abstract] [Full Text] [Related]

  • 17. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
    Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY.
    Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405
    [Abstract] [Full Text] [Related]

  • 18. Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis.
    Woo T, Adachi JD.
    Best Pract Res Clin Rheumatol; 2001 Jul; 15(3):469-81. PubMed ID: 11485341
    [Abstract] [Full Text] [Related]

  • 19. Bisphosphonates: expanded roles in the treatment of patients with cancer.
    Viale PH, Sanchez Yamamoto D.
    Clin J Oncol Nurs; 2003 Jul; 7(4):393-401. PubMed ID: 12929272
    [Abstract] [Full Text] [Related]

  • 20. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS, Fayans EP.
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.